Top Markets
Coin of the day
INOVIQ Ltd INOVIQ Ltd

INOVIQ Ltd

IIQ
Rang in Aktien #29964
INOVIQ Ltd specializes in the research, development, and commercialization of... INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Aktienkurs
$0.13400411
Marktkapitalisierung
$18.86M
Veränderung (1 Tag)
2.70%
Veränderung (1 Jahr)
-48.10%
Land
AU
Handel INOVIQ Ltd (IIQ)

Kategorie

P/B-Verhältnis für INOVIQ Ltd (IIQ)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von INOVIQ Ltd beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für INOVIQ Ltd von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
4.1431 -
US
2.7156 -
US
- -
CN
24.3791 -
US
27.366 -
US